Skip to main content

Advertisement

SpringerLink
Log in

Validation of overactive bladder questionnaire (1-week recall version) in medically complex elderly patients with overactive bladder

  • Original Article
  • Published:
International Urogynecology Journal Aims and scope Submit manuscript

Abstract

Introduction

The 33-item Overactive Bladder questionnaire (OAB-q; 1-week recall version) has been psychometrically validated in middle-aged, generally healthy patients with overactive bladder. The present analysis was conducted to determine the psychometric validity of the OAB-q in medically complex elderly patients.

Methods

OAB-q structure was evaluated using a second-order confirmatory factor analysis (CFA) model with five domains and one aggregated domain, using pooled data from two clinical trials (786 observations) for urgency urinary incontinence (UUI). Psychometric validity was evaluated with CFA, Cronbach coefficient α (CCA) for reliability, Spearman correlations for convergent validity, differences in OAB-q scores in relation to UUI severity and Patient Perception of Bladder Condition (PPBC) scores for known-groups validity, and effect size (ES) of differences in mean scores of OAB-q domains over time for treatment responsiveness.

Results

Participants were predominantly female (82.2%) and white (85.9%); mean age was 75.0 years. The second-order CFA was confirmed with a Bentler’s comparative fit index of 0.90, t values for path coefficients of >1.96, and standardized path coefficients of >0.40. OAB-q domains demonstrated good internal consistency (CCA >0.7). Convergent validity was supported by moderate correlations (0.4–0.7) between OAB-q domain and PPBC scores. Significant differences in OAB-q domain scores between groups with different symptom severity established known-groups validity. Significant changes in mean OAB-q scores from baseline to week 12 with moderate-to-large ES (0.50–0.80) demonstrated treatment responsiveness.

Conclusions

The OAB-q demonstrates reliability, concurrent and discriminant validity, and responsiveness to treatment. The evidence shows that the OAB-q is psychometrically sound for use in medically complex elderly patients with overactive bladder.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3

Similar content being viewed by others

References

  1. Abrams P, Cardozo L, Fall M et al. The standardisation of terminology of lower urinary tract function: report from the Standardisation Sub-committee of the International Continence Society. Am J Obstet Gynecol. 2002;187:116–126.

    Article  PubMed  Google Scholar 

  2. Liberman JN, Hunt TL, Stewart WF et al. Health-related quality of life among adults with symptoms of overactive bladder: results from a U.S. community-based survey. Urology. 2001;57:1044–1050.

    Article  CAS  PubMed  Google Scholar 

  3. Irwin DE, Milsom I, Kopp Z, Abrams P, Cardozo L. Impact of overactive bladder symptoms on employment, social interactions and emotional well-being in six European countries. BJU Int. 2006;97:96–100.

    Article  PubMed  Google Scholar 

  4. Coyne KS, Sexton CC, Kopp ZS, Ebel-Bitoun C, Milsom I, Chapple C. The impact of overactive bladder on mental health, work productivity and health-related quality of life in the UK and Sweden: results from EpiLUTS. BJU Int. 2011;108:1459–1471.

    Article  PubMed  Google Scholar 

  5. Helfand BT, Evans RM, McVary KT. A comparison of the frequencies of medical therapies for overactive bladder in men and women: analysis of more than 7.2 million aging patients. Eur Urol. 2010;57:586–591.

    Article  PubMed  Google Scholar 

  6. Irwin DE, Milsom I, Hunskaar S et al. Population-based survey of urinary incontinence, overactive bladder, and other lower urinary tract symptoms in five countries: results of the EPIC study. Eur Urol. 2006;50:1306–1314. discussion 1314-5.

  7. Coyne KS, Sexton CC, Vats V, Thompson C, Kopp ZS, Milsom I. National community prevalence of overactive bladder in the United States stratified by sex and age. Urology. 2011;77:1081–1087.

    Article  PubMed  Google Scholar 

  8. Chancellor MB, de Miguel F. Treatment of overactive bladder: selective use of anticholinergic agents with low drug-drug interaction potential. Geriatrics. 2007;62:15–24.

    PubMed  Google Scholar 

  9. Delafuente JC. Understanding and preventing drug interactions in elderly patients. Crit Rev Oncol Hematol. 2003;48:133–143.

    Article  PubMed  Google Scholar 

  10. Gibson W, Athanasopoulos A, Goldman H et al. Are we shortchanging frail older people when it comes to the pharmacological treatment of urgency urinary incontinence? Int J Clin Pract. 2014;68:1165–1173.

  11. U.S. Department of Health and Human Services. Guidance for Industry. Patient-Reported Outcome Measures: Use in Medical Product Development to Support Labeling Claims. Silver Spring, MD: U.S. Department of Health and Human Services, Food and Drug Administration; 2009.

  12. Cappelleri JC, Zou KH, Bushmakin AG, Alvir JMJ, Alemayehu D, Symonds T. Patient-reported outcomes: measurement, implementation and interpretation. Boca Raton: Chapman & Hall; 2013.

    Google Scholar 

  13. Saliba D, Elliott M, Rubenstein LZ et al. The Vulnerable Elders Survey: a tool for identifying vulnerable older people in the community. J Am Geriatr Soc. 2001;49:1691–1699.

    Article  CAS  PubMed  Google Scholar 

  14. Coyne K, Revicki D, Hunt T et al. Psychometric validation of an overactive bladder symptom and health-related quality of life questionnaire: the OAB-q. Qual Life Res. 2002;11:563–574.

    Article  CAS  PubMed  Google Scholar 

  15. Coyne KS, Matza LS, Thompson CL. The responsiveness of the Overactive Bladder Questionnaire (OAB-q). Qual Life Res. 2005;14:849–855.

    Article  PubMed  Google Scholar 

  16. Coyne KS, Gelhorn H, Thompson C, Kopp ZS, Guan Z. The psychometric validation of a 1-week recall period for the OAB-q. Int Urogynecol J. 2011;22:1555–1563.

    Article  PubMed  Google Scholar 

  17. Coyne KS, Matza LS, Kopp Z, Abrams P. The validation of the patient perception of bladder condition (PPBC): a single-item global measure for patients with overactive bladder. Eur Urol. 2006;49:1079–1086.

    Article  PubMed  Google Scholar 

  18. Coyne KS, Margolis MK, Hsieh R, Vats V, Chapple CR. Validation of the urinary sensation scale (USS). Neurourol Urodyn. 2011;30:360–365.

    Article  PubMed  Google Scholar 

  19. Wagg A, Khullar V, Marschall-Kehrel D et al. Flexible-dose fesoterodine in elderly adults with overactive bladder: results of the randomized, double-blind, placebo-controlled study of fesoterodine in an aging population trial. J Am Geriatr Soc. 2013;61:185–193.

    Article  PubMed  Google Scholar 

  20. DuBeau CE, Kraus SR, Griebling TL et al. Effect of fesoterodine in vulnerable elderly subjects with urgency incontinence: a double-blind, placebo controlled trial. J Urol. 2014;191:395–404.

    Article  CAS  PubMed  Google Scholar 

  21. Coyne KS, Matza LS, Thompson CL, Kopp ZS, Khullar V. Determining the importance of change in the overactive bladder questionnaire. J Urol. 2006;176:627–632. discussion 632.

  22. Abrams P, Artibani W, Gajewski JB, Hussain I. Assessment of treatment outcomes in patients with overactive bladder: importance of objective and subjective measures. Urology. 2006;68:17–28.

    Article  PubMed  Google Scholar 

Download references

Acknowledgements

The authors thank Tara Symonds and Doug Chapman for their contributions to the protocol development and early involvement in this analysis.

Author information

Authors and Affiliations

  1. Outcomes & Evidence, Global Health & Value Pfizer Inc, 235 East 42nd Street, New York, NY, 10017, USA

    Alexandra I. Barsdorf, Martin Carlsson & Sheila Quinn

  2. Pfizer Inc, Groton, CT, USA

    Andrew G. Bushmakin & Joseph C. Cappelleri

  3. Pfizer Inc, La Jolla, CA, USA

    Andreas Pleil

Authors
  1. Alexandra I. Barsdorf
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Martin Carlsson
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Andrew G. Bushmakin
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Sheila Quinn
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Joseph C. Cappelleri
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Andreas Pleil
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Alexandra I. Barsdorf.

Ethics declarations

Funding

This study was sponsored by Pfizer Inc. Medical writing assistance was provided by Patricia B. Leinen, PhD, of Complete Healthcare Communications, LLC (Chadds Ford, PA), a CHC Group company, and was funded by Pfizer Inc.

Conflicts of Interest

None.

Electronic supplementary material

Below is the link to the electronic supplementary material.

ESM 1

(DOCX 240 kb)

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Barsdorf, A.I., Carlsson, M., Bushmakin, A.G. et al. Validation of overactive bladder questionnaire (1-week recall version) in medically complex elderly patients with overactive bladder. Int Urogynecol J 28, 1857–1863 (2017). https://doi.org/10.1007/s00192-017-3305-8

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00192-017-3305-8

Keywords

Search

Navigation